Licensing of Medical Treatments

NewsGuard 100/100 Score

Introduction
Licensing of Medical Treatments: UK Process
Licensing of Medical Treatments: US Process
Unlicensed and Off-label Medicines
Conclusion
References


The pharmaceutical industry is considered one of the most highly regulated industries worldwide. Various countries have their own regulatory authority, such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK or the Food and Drug Administration (FDA) in the US. These organizations regulate the drug development process, licensing, registration, manufacturing, marketing, and labeling of medicines.

A comprehensive process is followed in the UK and the US by which medicines are licensed and approved for treating a specific disease or condition. This process can take several years before licensing is granted.

FDA Approved

Image Credit: Panchenko Vladimir/Shutterstock.com

Licensing of Medical Treatments: UK Process

For medicines to be used for treatment in the UK, marketing authorization is required by the MHRA. The MHRA is accountable for regulating all medicines and medical devices in the UK, ensuring that they are both effective and acceptably safe for treatment.

After laboratory and animal testing, the licensing process is initiated by first receiving permission to conduct human clinical trials on the drug. This involves an extensive regulatory process whereby peer-reviewed groups, including health care professionals, as well as review committees, such as the Research Ethics Committee (REC) in the UK, review the protocol and data provided. These groups assess whether the trial is safe and also ethical.

Once permission to run a trial is granted, clinical research for the drug may begin. A summary of product characteristics, labeling, and all the data from the clinical trials must be provided to the MHRA for assessment. These documents include relevant information on dosage, administration, efficacy, safety profile, etc.

The MHRA assessment team is composed of specialist experts who will evaluate all documents provided for the medicine. The duration of the assessment process varies depending on several factors, including the type of medicine being analyzed, the quality of initial information supplied, whether any further details are required, etc.

If the medicine is effective and acceptably safe, it is given a product licensed by the MHRA and can be prescribed for treatment. The MHRA is also responsible for regulating the licensed medicine's manufacturing, distribution, and supply, ensuring it meets all necessary safety and quality standards.

Licensing of Medical Treatments: US Process

The licensing process in the US is similar; however, all medicines are approved by the US FDA's Centre for Drug Evaluation and Research (CDER). This organization oversees the medicine approval process before it is marketed.

In the US, the FDA performs the task of regulating and approving drugs. The medication is first tested in laboratories and on animals to determine how it may work in humans and its safety profile. An Investigational New Drug (IND) application is then submitted to the FDA, which will ensure the medicine's safety for application in human clinical trials. After an extensive review, the medicine progresses to testing in human clinical trials.

After these clinical trials, a New Drug Application (NDA) is submitted to the FDA. This includes all data gathered from animal and human studies of the IND. The FDA will review data regarding the efficacy, safety, and quality of the medicine as well as the package insert.

The FDA Advisory Board, composed of an independent team of specialized clinicians, scientists, chemists, pharmacologists, and patient representatives, meets to discuss and evaluate the NDA with the FDA reviewers and product manufacturers.

After these discussions, the Advisory Board will vote for the approval of the medicine or not. Although not required to, the FDA usually follows the Advisory Boards decision. Once approved, the medicine is available in the US as a treatment.

Through the Prescription Drug User Free Act (PDUFA), companies can pay for the drug approval process to be quickened by providing the FDA with access to more resources. Several imperative drugs have been approved through this act, primarily for diseases such as Cancer, AIDS, and heart disease.

Certain medicines may also receive special designation, including Fast Track, Breakthrough Therapy Designation (BTD), and Priority Review. These are typically granted for drugs that are either the first available treatment for a disease or demonstrate a significant clinical benefit over its existing competitors.

Medicine

Image Credit: fizkes/Shutterstock.com

Unlicensed and Off-label Medicines

There are instances where unlicensed medicine is prescribed by a healthcare professional. This occurs if there are no suitable licensed alternatives that will be beneficial for the patient. Unlicensed medicines are commonly used in pediatrics, palliative care, and psychiatry and less frequently in other areas of medicine.

Off-label medicines may also be prescribed, where a licensed medicine is used outside the terms defined by the license. For instance, an off-label medication may be used for a different disease or condition, a different patient group, or administered at a different dose. An example of an off-label medication is Spironolactone, which is indicated for patients with heart failure but has an off-label indication for hypertension.

Conclusion

The licensing of medicines involves a highly regulated process. Regulatory organizations such as the MHRA and FDA are responsible for ensuring the safety, quality, and efficacy of drugs available to treat diseases.

References:

Last Updated: Feb 1, 2023

Naveen Dha

Written by

Naveen Dha

Naveen graduated from King’s College London where she attained a Bachelor of Science in Biochemistry. Within this course, she chose to study topics pertaining to the biology of cancer, molecular immunology, molecular biology, and protein structure. Throughout her degree, she partook in writing various practical proposals, reports, and literature reviews whilst also gaining multifaceted laboratory and research experience. It was through these projects that Naveen discovered her interest for scientific writing as it allowed her to remain intellectually curious, creative, and detail-orientated.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dha, Naveen. (2023, February 01). Licensing of Medical Treatments. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/life-sciences/Licensing-of-Medical-Treatments.aspx.

  • MLA

    Dha, Naveen. "Licensing of Medical Treatments". News-Medical. 19 April 2024. <https://www.news-medical.net/life-sciences/Licensing-of-Medical-Treatments.aspx>.

  • Chicago

    Dha, Naveen. "Licensing of Medical Treatments". News-Medical. https://www.news-medical.net/life-sciences/Licensing-of-Medical-Treatments.aspx. (accessed April 19, 2024).

  • Harvard

    Dha, Naveen. 2023. Licensing of Medical Treatments. News-Medical, viewed 19 April 2024, https://www.news-medical.net/life-sciences/Licensing-of-Medical-Treatments.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First study to report isolation of M. saskatchewanense from medical devices